Table 2

Clinicopathological characteristics of methylation of p16 in non-small cell lung cancer

MethylationPa
Absent (n=134)Present (n=51)
Ageb66±1169±90.19
Sex
 Female6519
 Male69320.19
Pack-yearsb51±3869±430.007
Years smokedb36±1644±160.0009
Years quitb8±104±70.03
Smoking status
 Never112
 Ex-smoker7621
 Current47280.05
Asbestos exposurec
 No11643
 Yes1661.00
DAP-K methylation
 No9741
 Yes37100.35
Stagec
17923
 22114
 32713
 4500.11
Histologyc
 Adenocarcinoma7321
 Squamous cell carcinoma3524
 Other2550.07
K-ras mutation
 No11043
 Yes2480.83
p53 exons 5–10c
 Wild-type9633
 Mutant34170.36
  • a Wilcoxon rank sum test and Fisher’s exact (or χ2) test was used for continuous and categorical variables, respectively.

  • b Mean ± SD.

  • c Asbestos exposure, stage, histology, and p53 exon 5–10 data are missing for 4, 3, 2, and 5 patients, respectively.